Heparin-induced hyperkalemia: a prospective study.
- G. González‐Martin, M. S. Díaz-Molinas, Á. Martínez, M. Ortiz
- MedicineInternational journal of clinical pharmacology…
- 1 November 1991
The frequency of hyperkalemia did not correlate with age, sex, renal impairment or with previous use of anti-inflammatory drugs, heparin or aspirin, and it was more frequent in patients with diabetes mellitus, metabolic acidosis and long-term Heparin therapy.
Matched sibling donors versus alternative donors in allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia in México
- L. Rodríguez, Ó. González-Llano, O. Gonzalez-Ramella
- 1 September 2015
There is still much room for improvement particularly in children allografted with AD and in the supportive care, and the development of an economicwise designed prospective project with MSD or matched unrelated donor HSCTs as a first line of treatment of children with SAA as a unified national trial could address these issues.
Adverse drug reactions (ADRs) in patients with heart diseases. Comparison between patients without and with heart failure.
It is suggested that heart failure may be a determinant of frequency and characteristics of ADRs, which are significantly more frequent in patients with heart failure than in patients without heart failure.
2878 – DRUG SURVEILLANCE OF HOSPITALIZED PATIENTS. THE UNIVERSITY OF CHILE EXPERIENCE
- C. Naranjo, I. Ruiz, U. Busto, C. Domecq, M. Ortiz, G. González
HOSPITALISATION FOR MYASTHENIA: ARE WE DOING SOMETHING WRONG?
- J. Sussman, M. Ortiz
- MedicineJournal of Neurology Neurosurgery & Psychiatry
- 1 October 2014
Patients with autoimmune MG may deteriorate despite treatment, and non-myasthenologists appear overcautious with all treatments but especially steroids, frequently sub-optimally managed, possibly contributing to hospital admission.
5PSQ-027 Early real-world effectiveness and safety of secukinumab in patients with psoriasis
- M. Ortiz, P. R. Torres, A. G. Lobón
- 1 March 2018
In this short-term study, secukinumab shows high efficacy, achieving completely clear skin in more than 50% of patients at week 12, both in naive patients and in those who failed prior biologics.
4CPS-027 Real-world effectiveness of evolocumab and alirocumab at 12 months of treatment
- M. Gómez Zamora, P. Rovira Torres, JR Urgeles Planella
- Medicine, BiologySection 4: Clinical Pharmacy Services
- 1 March 2019
Background Alirocumab and Evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) that have been authorised by the Autonomous Health Service under the following conditions:…
5PSQ-040 Security profile of ibrutinib as monotherapy in patients with chronic lymphocytic leukaemia: experience in a tertiary hospital
- C. Fernández Cuerva, C. Ortega de la Cruz, M. Ortiz, M. Muñoz Castillo
- 1 March 2020
In the authors' patients, ibrutinib had an adequate safety profile, highlighting haemorrhage as the most serious AE, and periodic follow-up of patients is necessary to assess adverse reactions and the need for temporary suspension in patients.